Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine QL block in hip arthroscopy
NCT03506620Phase 4Withdrawn
- Sponsor
- Columbia University
- Start
- Jan 2019
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised, double-blind trial of ropivacaine in Femoroacetabular impingement (FAI), sponsored by Columbia University. Primary endpoints: Pain Score at 7 days and Oral Morphine Equivalents at 7 days. Planned start Jan 2019; status: withdrawn.
02
Drugs
ropivacaine
03
Conditions
Femoroacetabular impingement (FAI)
Beyond the preview
Go deeper on NCT03506620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506620.